Ziemer takes Amadeus back from AMO

Article

The Ziemer group is to assume all worldwide marketing, sales and support duties for AMO's Amadeus II automated microkeratome.

The Ziemer group is to assume all worldwide marketing, sales and support duties for AMO's Amadeus II automated microkeratome.

The Amadeus product line was originally developed by a subsidiary of Ziemer and the rights were sold to AMO in 1999. Ziemer has since developed a global marketing and distribution network that it can rely on to market the Amadeus.

Ziemer also sells the Femto LDV femtosecond laser, making it the only ophthalmic company to offer a choice of microkeratome or femstosecond lasers for corneal refractive surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.